| Sales revenue | 2,780a | 2,775.5a |
| Cost of sales | -1,573.3a | -1,541.5a |
| Gross profit on sales | 1,206.7a | 1,234a |
| Selling and distribution costs | -479.8a | -448.9a |
| Research and development costs | -144.1a | -129.5a |
| General administrative expenses | -168.7a | -167.1a |
| Other operating income | 37a | 40.7a |
| Other operating expenses | -80.6a | -79.8a |
| Earnings before interest and taxes (EBIT) | 370.6a | 449.5a |
| Financial income | 45.4a | 94.4a |
| Financial expenses | -196.7a | -141.9a |
| Financial result | -151.3a | -47.6a |
| Profit before tax | 219.2a | 401.9a |
| Income taxes | -40.7a | -89.2a |
| Net profit for the period | 178.5a | 312.7a |
| Attributable to | — | — |
| Equity holders of Sartorius Stedim Biotech | 175.1a | 310.3a |
| Non-controlling interest | 3.4a | 2.4a |